Accuracy of Magnetic Resonance Enterography in Assessing Response to Therapy and Mucosal Healing in Patients With Crohn's Disease

SICUS and CEUS imaging in Crohn’s disease: an update

“…Anti-tumour necrosis factor (TNF) a agents are effective in the treatment of Crohn's disease CD because they can induce clinical remission and mucosal healing in most patients. Nevertheless, CD is a transmural process and data on transmural healing induced by these molecules are still lacking [50][51][52][53]. A recent study has evaluated transmural healing, which is defined as normalization of bowel wall thickening, using bowel sonography in patients with CD treated with biologics and immunosuppressors and its correlation with clinical remission and mucosal healing [52].…”

Role of 18F-fluorodeoxyglucose Positron Emission Tomography in the Monitoring of Inflammatory Activity in Crohnʼs Disease

“…9/13 patients who completed PET scanning both at baseline and a median [range] of 12 [11][12][13][14][15][16][17][18] weeks after initiation of anti-TNF treatment had favourable clinical responses 27 (median [range] responder ΔHBI = 5 [3][4][5][6][7][8][9]; non-responder ΔHBI = 1[-1-2]), (Table 1). …”

“…Table 6 4 Test-retest repeatability 5 patients (1 female) with active CD were recruited for this arm of the study, and 4 completed the two scans within a median [range] period of 7 [4][5][6][7][8][9][10][11][12] days. The repeatability of the PET measures were estimated in segments with a signal focus > LivSUVMEAN (Table 7).…”

“…Biomarkers currently in use in clinical practice (e.g., C-reactive protein [CRP] and faecal calprotectin) lack sensitivity and specificity 5,4 . Recently, imaging biomarkers, such as the Magnetic Resonance Index of Activity (MaRIA) have been validated against colonoscopy as a measure of mucosal and transmural disease load in cross sectional studies [6][7][8] . However a significant unmet need remains for non-invasive longitudinal biomarkers reflecting disease activity.…”

Editorial: can MRI enterography be an efficient tool for patient selection in clinical trials?

“…2 There is robust evidence that quantitative MRI activity scores such as MaRIA and MR enterography global score are effective, 3,4 have reasonable inter-reader agreement 5 and are responsive to the effects of therapy. [6][7][8] The ability of MRI to evaluate the full burden of disease, including extra-enteric complications and bowel inaccessible to colonoscopy, are significant advantages. These new data from Coimbra et al tentatively suggest that MRI may be an effective triage tool for multi-centre clinical trials.…”